Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. Developing a safe and effective vaccine against COVID-19 is a viable long-term solution to control the pandemic. As one of the two inactivated severe acute respiratory syndrome virus 2 (SARS-CoV-2) vaccines developed in China that entered the WHO emergency use list, Sinopharm BBIBP-CorV, an aluminum-hydroxide-adjuvanted, inactivated whole-virus vaccine, has been widely distributed, with more than 400 million doses administered in more than 40 countries. The evidence of the safety, efficacy, and effectiveness of BBIBP-CorV is gathered and reviewed. We further comment on one of the latest papers that disclosed the effectiveness results between BBIBP-CorV, rAd26-rAd5, and ChAdOx1.
Funding Information
  • National Key Research and Development Program of China (2021YFC2301604, BMU20170607, BMU2021PY005, L202007)
  • Central Universities and Peking University Health Science Center (2021YFC2301604, BMU20170607, BMU2021PY005, L202007)
  • Fostering Young Scholars’ Scientific & Technological Innovation (2021YFC2301604, BMU20170607, BMU2021PY005, L202007)
  • Beijing Natural Science Foundation and Haidian Original Innovation (2021YFC2301604, BMU20170607, BMU2021PY005, L202007)

This publication has 23 references indexed in Scilit: